Kailera Therapeutics (NASDAQ:KLRA) Stock Rating Upgraded by Zacks Research

Kailera Therapeutics (NASDAQ:KLRA) was upgraded by equities researchers at Zacks Research to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

A number of other analysts also recently weighed in on KLRA. Leerink Partners started coverage on Kailera Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $36.00 price objective for the company. Wall Street Zen upgraded Kailera Therapeutics to a “hold” rating in a report on Saturday, April 25th. Evercore started coverage on Kailera Therapeutics in a report on Tuesday. They issued an “outperform” rating for the company. JPMorgan Chase & Co. started coverage on Kailera Therapeutics in a report on Tuesday. They issued an “overweight” rating and a $30.00 price objective for the company. Finally, Jefferies Financial Group started coverage on Kailera Therapeutics in a report on Tuesday. They issued a “buy” rating and a $48.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Kailera Therapeutics has an average rating of “Buy” and an average price target of $42.75.

Kailera Therapeutics Stock Up 1.8%

NASDAQ KLRA opened at $21.50 on Wednesday. Kailera Therapeutics has a twelve month low of $20.86 and a twelve month high of $28.23.

Insiders Place Their Bets

In other Kailera Therapeutics news, Director Adam Koppel purchased 1,562,500 shares of the firm’s stock in a transaction on Monday, April 20th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $25,000,000.00. Following the acquisition, the director owned 22,583,268 shares in the company, valued at approximately $361,332,288. The trade was a 7.43% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Andrew T. Kaplan purchased 8,398,438 shares of the firm’s stock in a transaction on Monday, April 20th. The shares were acquired at an average price of $16.00 per share, with a total value of $134,375,008.00. Following the completion of the acquisition, the director owned 26,255,581 shares in the company, valued at approximately $420,089,296. This trade represents a 47.03% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 10,460,938 shares of company stock worth $167,375,008.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.